There is provided a production method for a microcapsule in which cells are encapsulated with alginic acid and a polycation, the method including dropwise adding a cell suspension containing cells and alginic acid into a calcium ion-containing solution to obtain a liquid droplet in which the cells are encapsulated in alginic acid, and immersing the liquid droplet in a coating liquid containing a polycation, to obtain the microcapsule, where the coating liquid contains a calcium ion or a barium ion at a concentration of 0.1 mM or more and 50.0 mM or less. According to the production method of the present invention, it is possible to produce a microcapsule having a uniform shape and particle size.

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.

Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.

The present invention relates to a stable self-assembling graphene oxide-protein matrix comprising a disordered protein (DP) and graphene oxide (GO), wherein the DP has an opposite charge to the GO, further wherein the graphene oxide-protein matrix is in the form of a 3D structure having a lumen defined by a membrane having an inner and outer surface. The invention further relates to methods and kits for preparing such a graphene oxide-protein matrix and its uses.

Compositions and peptides for enhancing formation of cartilage in a site of a cartilage injury or defect, or joint condition, and methods of the use of the compositions and peptides in such treatments. Examples of the sites may include a knee, ankle, wrist, shoulder, elbow, patella, hip, vertebrae, femoral head, temporomandibular joint, glenoid of the scapula, jaw, and growth plate.

Novel articles of manufacture are described based on a combination of an adjunct material and microcapsules made by an improved process. The improved microcapsules are chitosan urea and encapsulate a benefit agent. The process comprises combining an adjunct material formed of microcapsules formed by a water phase comprising hydrolyzing chitosan in an acidic medium at a pH of 6.5 or less for an extended period and combining with a polyisocyanate. The reaction product of the hydrolyzed chitosan and polyisocyanate yields a microcapsule having improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.

The absorbent article comprises at least a topsheet layer and a backsheet layer, each layer having a body facing surface and a garment facing surface, and longitudinal and transversal edges, the article having a longitudinal front portion, a longitudinal back portion and a crotch portion located between the front and the back portion. The article comprises a first and a second zone of microencapsulated phase change material on a surface of a layer of the article. The first and second zones are selected form zones having different microencapsulated phase change materials, different concentrations of a microencapsulated phase change material or comprise microencapsulated phase change material having different phase change temperature intervals.

A soft tissue device can incorporate a composite material comprising a gel and at least one nanostructure disposed within the gel. A soft tissue device can further incorporate biologically active materials such as cells, tissues. A method for healing a soft tissue defect while promoting soft tissue regeneration can include applying a soft tissue device to a soft tissue defect, wherein the composite material includes a gel and a nanostructure disposed within the gel. A method for manufacturing a soft tissue device for use in healing soft tissue defects can include providing a gel, disposing nanofibers within the gel, and a biologically active material.

A therapeutic microporous hydrogel scaffold for use in an animal is disclosed that releases one or more therapeutic agents or drugs. The scaffold uses a drug-releasing microporous annealed particle system that encapsulates drug-loaded nanoparticles into particle building blocks. By modulating nanoparticle hydrophilicity and pre-gel solution viscosity, the particle building blocks were generated with consistent and homogeneous encapsulation of nanoparticles. The scaffold may be used to treat myocardial infarction (MI) using, for example, the drugs forskolin (F) and Repsox (R). The intramyocardial injection of the pre-annealed hydrogel slurry of particles that formed the resultant scaffold improved left ventricular functions, which were further enhanced with increased angiogenesis and reduced fibrosis and inflammatory response. This therapeutic microporous hydrogel scaffold platform represents a new generation of microgel particles for MI therapy and will have broad applications in regenerative medicine and disease therapy.

The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as sup-ports comprising the viral micro particles for the locating the viral microparticles in a wound or in the vicinity of a wound.